Nils Bolstad

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 789 citations

Oncology, Clinical Translation, Originator Infliximab +10

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases

Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll et al. · JAMA · 2021 · 147 citations · Full text

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases

Silje Watterdal Syversen, Guro Løvik Goll, Kristin Kaasen Jørgensen et al. · JAMA · 2021 · 117 citations · Full text

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

Guro Løvik Goll, Kristin Kaasen Jørgensen, J. Sexton et al. · Journal of Internal Medicine · 2019 · 116 citations · Full text

Human epididymis protein 4 reference limits and natural variation in a Nordic reference population

Nils Bolstad, Miriam Øijordsbakken, Kjell Nustad et al. · Tumor Biology · 2011 · 109 citations · Full text

Healthy Subjects, Natural Variation, Genetics +18